Replies to post #133190 on Biotech Values

[biotech jim]

I'm sure rkrw will be twice as hard to beat in '12

Are you saying that rkrw is a lock to win in 2012 so the rest of us should not even consider entering the SI biotech charity contest? There is a saying in this business that past history is...

[mcbio]

We have to get mcbio to do some work around here. He wins (almost official) a charity contest and gets everyone to do his work! Just kidding congrats mcbio very nice job beating the defending champ (I'm sure rkrw will be twice as hard to beat in '12)

It is my understanding that the champ gets full ride for the year for everyone to do his/her bidding. I plan to take full advantage of that if I am so lucky to pull off the victory. ; ) Seriously though, thanks for the props and would be quite an honor if I were to finish first given all the heavyweights, including yourself, around these parts.

oh and where is summary to the 3 hour Array Analyst Day its been over for 4 hours already!

Yes, yes, I will try to give a listen and post any relevant notes. Not sure if I can survive a 3 hour marathon though!

[mcbio]

ARRY - Analyst Day CC notes (12/16/11)

[FWIW, I only listened to the first hour of this CC related to ARRY's MEK inhibitors, and not the latter portion that is supposed to be devoted to ARRY-520 and ARRY-614, insofar as it's the MEK inhibitors that I view as the key potential future value drivers for ARRY.]

1. Slide 14 - MEK pathway mutations:

(a) BRAF melanoma - 43%;
(b) GNAQ/GNA11 ocular melanoma - 59%;
(c) KRAS NSCLC - 16%;
(d) KRAS pancreatic - 57%; and
(e) KRAS colorectal - 35%.

2. Buzz for MEK+PI3K/Akt inhibitor or MEK+taxanes.

3. Slide 26 - BRAF mutant melanoma data

(a) Vemurafenib Phase 3 data - ORR = 48% and mPFS = 5.3 months
(b) selumetinib + DTIC Phase 1b data - ORR = 56% and mPFS = 7.1 months

4. Slide 27 - KRAS NSCLC data

ARQ197 + erlotinib only showed 2.3 months mPFS in 2nd-line KRAS NSCLC patients . Same for sorafenib single agent.

5. 38 minute mark - In regards to the MEK162 Phase 1 expansion trial in biliary tract cancer patients, ARRY will be presenting results at ASCO GI in January where ARRY has seen PRs and CRs in single-agent trials of MEK162 in a heavily pre-treated patient population. (Someone please listen to the 38 minute mark and let me know if my ears have deceived me; seems pretty clear to me that the presenter said there have been both PRs and CRs seen in this trial. It is of course possible that he misspoke.)